Trials / Unknown
UnknownNCT05552248
Assessment of the Safety and Performance of a Lumbar Belt
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Decathlon SE · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Decathlon has developed the Lumbar belt Soft 300 and Mid 500 products which are medical devices designed to reduce pain and improve function during sport practice for athletes with a common subacute or chronic low back pain. The objective of this multicentre study is to collect data on the related clinical complications and clinical outcomes of market-approved Decathlon Lumbar belt range of products to demonstrate safety and performance of these devices in a real-world setting. Outcome data collected from this study will provide the basis for Post-Market Surveillance (PMS) reporting, Clinical Study Report (CSR), Clinical Evaluation Report (CER) on Decathlon lumbar belt Soft 300/ Mid 500 devices and support peer-reviewed publications on products performance and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | LumbarBelt SOFT 300 | 15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks. |
| OTHER | Control group LumbarBelt SOFT 300 | 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks. |
| DEVICE | LumbarBelt MID 500 | 15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks. |
| OTHER | Control group LumbarBelt MID 500 | 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks. |
Timeline
- Start date
- 2022-09-23
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2022-09-23
- Last updated
- 2023-01-17
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05552248. Inclusion in this directory is not an endorsement.